Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023
- Futures edge up on Fed pivot hopes, jobs data in focus
- MongoDB delivers upbeat guidance after Q3 results beat
- Stocks, gold gain as investors stay cheery on rate outlook
- SentinelOne rallies 20% as Q3 results suggest momentum is accelerating
- PayPal (PYPL) stock falls as Bank of America downgrades on 'too high' 2024 estimates
The Company will also be participating in one-on-one meetings, which can be arranged with H.C. Wainwright representatives.
The Co-Dx PCR Home platform is subject to FDA review and is not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-the-hc-wainwright-25th-annual-global-investment-conference-on-september-11-13-2023-301920689.html
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Green and Low-carbon Transformation Practices in Jiangsu Province of China Have Attracted Attention at COP28
- LEAVE A BOX AND GET A BOX: PIZZA HUT LAUNCHES "REVERSE DELIVERY" DOORMAT TO GIFT PIZZA TO DELIVERY DRIVERS THIS HOLIDAY SEASON
- Vena Named a Visionary in Financial Close and Consolidation Solutions in Gartner's 2023 Magic Quadrant
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Related EntitiesH.C. Wainwright, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!